This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Relistor (Oral)

Valeant Pharmaceuticals International, Inc.

Drug Names(s): Methylnaltrexone (Oral), Oral MNTX

Description: BioMedTracker has separate drug profiles for Relistor. Please also see Relistor SC and Relistor IV.

Relistor is an opioid antagonist with limited ability to cross the blood-brain barrier. It is a drug designed to reverse the constipation caused by opium-based analgesics without interfering with the pain relief of opioids.

Deal Structure: Progenics and UR Labs
Progenics licensed worldwide exclusive rights to Relistor from UR Labs in October 2001.

Wyeth (now Pfizer) and Progenics
On December 23, 2005, Wyeth Pharmaceuticals and Progenics Pharmaceuticals announced that they entered into an exclusive, worldwide agreement for the joint development and commercialization of Relistor for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction.

Under the terms of the collaboration, Wyeth receives worldwide rights to Relistor, and Progenics retains an option to co-promote the product in the United States. Wyeth will develop oral Relistor worldwide. The transaction includes an upfront payment of $60 million to Progenics with as much as an additional $356.5 million payable upon achievement of certain milestones. Wyeth will pay Progenics royalties on worldwide sales of Relistor and co-promotion fees within the United States. Additionally, Wyeth is...See full deal structure in Biomedtracker

Partners: Progenics Pharmaceuticals, Inc.


Relistor (Oral) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug